Xu Teng
- Cancer Research top 1%
- Cancer-related molecular mechanisms research 12
- MicroRNA in disease regulation 5
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery 4
- Molecular Biology top 5%
- RNA modifications and cancer 13
- Epigenetics and DNA Methylation 8
- RNA Research and Splicing 8
- Cancer-related gene regulation 5
- Biomedical Engineering top 5%
- Pharmaceutical Science top 5%
-
- Ferroptosis and cancer prognosis 4
- Co-authors
- Fangqiong TangDong ChenJunqi HeXinglu HuangShi‐Mei ZhuangHang SuYunfei YuanJian‐Rong Yang
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Xu Teng
57 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Cancer Research 1.4k
- Biomaterials 834
- Molecular Biology 2.1k
- Biomedical Engineering 767
- Pharmaceutical Science 99
Countries citing papers authored by Xu Teng
This map shows the geographic impact of Xu Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Teng more than expected).
Fields of papers citing papers by Xu Teng
This network shows the impact of papers produced by Xu Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Teng. The network helps show where Xu Teng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xu Teng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 17 | |
| 4 | 2023 | 12 | |
| 5 | 2023 | 2 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 45 | |
| 8 | Micronutrient Supplementation to Reduce Cardiovascular Riskbreakdown → | 2022 | 111 |
| 9 | 2021 | 46 | |
| 10 | 2021 | 4 | |
| 11 | 2020 | 2 | |
| 12 | 2020 | 31 | |
| 13 | 2017 | 10 | |
| 14 | 2016 | 15 | |
| 15 | 2015 | 49 | |
| 16 | 2011 | 33 | |
| 17 | 2010 | 297 | |
| 18 | 2010 | 98 | |
| 19 | MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicitybreakdown → | 2009 | 533 |
| 20 | 2008 | 37 |
About Xu Teng
Xu Teng is a scholar working on Cancer Research, Molecular Biology and Hematology, having authored 58 papers that have together received 3.9k indexed citations. Recurring topics across this work include RNA modifications and cancer (13 papers), Cancer-related molecular mechanisms research (12 papers), Epigenetics and DNA Methylation (8 papers), RNA Research and Splicing (8 papers), MicroRNA in disease regulation (5 papers), Cancer-related gene regulation (5 papers), Ferroptosis and cancer prognosis (4 papers) and Nanoparticle-Based Drug Delivery (4 papers). The work is most often cited by research in Cancer Research (1.4k citations), Biomaterials (834 citations) and Molecular Biology (2.1k citations). Xu Teng has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Fangqiong Tang, Dong Chen, Junqi He, Xinglu Huang, Shi‐Mei Zhuang, Hang Su, Yunfei Yuan, Jian‐Rong Yang, Ying Zhu and Linlin Li. Their work appears in journals such as Nucleic Acids Research, Journal of Biological Chemistry and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.